The symposium begins today, April 23, 2014, and concludes on April 27, 2014. "We are pleased that two abstracts highlighting EpiFix® allografts were selected for oral presentation and one of them, authored by Charles M. Zelen, DPM, FACFAS, FACFAOM, FAPWCA; Thomas E. Serena MD, FACS and Robert J. Snyder, DPM, MSc, CWS, was selected as 3 rd place for Best Oral Abstract," said Parker H. "Pete" Petit, CEO of MiMedx Group, Inc. (NASDAQ: MDXG ). "Clinically, EpiFix® is associated with more rapid healing and prevention of longer term complications including infection and amputation," said Dr. Stephen Bergquist, Medical Director for Jackson -Madison County Hospital. "From the cost-of-care perspective, EpiFix requires the use of fewer grafts leading to overall cost savings," he continued.